- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02003040
Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions
Study Overview
Detailed Description
Rehospitalizations for heart failure have been linked to poor clinical outcomes, rates remain high despite different attempts to decrease them . Clinical indicators of volume congestion at time of discharge are associated with increased rates of readmission . Clinical evaluation of volume status remains the gold standard in determination of readiness and timing of hospital discharge, however identification of persistent congestion might prove difficult .
Assessment of the right atrial pressure can be done non-invasively at the bedside; however, precision and accuracy of this method are variable . Echocardiography is a valuable tool in the estimation of elevated central pressure , this, however is time consuming and requires trained personnel. While invasive measurements provide accurate estimation of central venous pressure, it is an impractical approach in most patients, notwithstanding the risks associated with the insertion of a catheter into the central circulation .
Since a significant proportion of readmitted patients return to hospital with congestive symptoms, attempts have been made to improve our ability to assess volume status . Current clinical evidence suggests that BNP-guided management of patients with congestive heart failure can decrease all-cause mortality and heart failure rehospitalization. However, biological variation for natriuretic peptides is high , and optimal targets are difficult to determine in individual patients.
The Mespere Venus 1000 system is a non-invasive tool that has previously shown reliable correlation and accuracy with central venous pressure obtained invasively in the catheterization laboratory and good correlation with jugular venous pressure at the bedside.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 and older
- Patient admitted to St. Michael's Hospital with a main clinical diagnosis of decompensated heart failure.
- Signed informed consent
Exclusion Criteria:
- Lack of patient consent.
- Presence of known AV dialysis fistula.
- Allergy to adhesive tape from Mespere Venus 1000 system.
- Known central vein stenosis.
- Ongoing photodynamic therapy.
- Assisted ventilation.
- Associated acute coronary syndrome
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
St. Michael's Hospital Patients
Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
|
An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject.
A CVP measurement is recorded at time of patient's hospital admission and discharge.
CVP readings will remain concealed from the treating team.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in non-invasive central venous pressure (NICVP) at time of hospital discharge
Time Frame: time of hospital admission (baseline) and time of hospital discharge
|
To determine if NICVP (taken at time of hospital admission and discharge) from the Mespere Venus 1000 CVP System can predict 30-day hospital readmissions for acute decompensated heart failure.
|
time of hospital admission (baseline) and time of hospital discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NT-proBNP
Time Frame: 1 visit
|
To investigate if there's a correlation between CVP measurements from the Mespere Venus 1000 CVP System and NT-proBNP at time of hospital admission and discharge
|
1 visit
|
Patient's weight
Time Frame: 1 visit
|
To investigate if there's a correlation between CVP measurements from the Mespere Venus 1000 CVP System and weight change at time of hospital admission and discharge
|
1 visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Abdul Al-Hesayen, MD, Unity Health Toronto
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STP-9000011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHF
-
University of PalermoCompleted
-
Medical University of GrazAIT Austrian Institute of Technology GmbHUnknown
-
Massachusetts General HospitalRecruitingCHF | Control | ADHFUnited States
-
Aventyn, Inc.Arizona State University; Intel Corporation; TwinEpidemic; Heart Health Organization...RecruitingHeart Failure | ADHF | Acute MIUnited States
-
Nile TherapeuticsIntegriumCompletedHeart Failure | Chronic Heart Failure | CHF | ADHFUnited States
-
Nuwellis, Inc.TerminatedHeart Failure | Cardiac Failure | Acute Decompensated Heart Failure (ADHF)United States
-
Echosense Ltd.Terminated
-
RWTH Aachen UniversityPhilips Technology Aachen GermanyUnknownAcute Decompensated Heart Failure (ADHF) | Acute Cardiogenic Pulmonary Edema (ACPE)Germany
-
ProcyrionRecruitingHeart Failure | Heart Failure, Diastolic | Cardio-Renal Syndrome | Heart Failure, Systolic | Heart Failure, Congestive | Heart Failure; With Decompensation | Cardiorenal Syndrome | ADHFUnited States
Clinical Trials on Mespere Venus 1000 CVP System
-
Mespere Lifesciences Inc.Wayne State UniversityUnknownSevere Sepsis | Acute Heart FailureUnited States
-
Mespere Lifesciences Inc.Unknown
-
Boston Children's HospitalMespere Lifesciences Inc.TerminatedCentral Venous PressureUnited States
-
Mespere Lifesciences Inc.CompletedPatients Referred to St. Michael's Hospital Echocardiography LabCanada
-
Mespere Lifesciences Inc.University of MichiganCompletedCentral Venous PressureUnited States
-
Venus MedTech (HangZhou) Inc.UnknownAortic Valve Stenosis | Aortic Valve CalcificationChina
-
Venus ConceptCompletedCircumference Reduction | Wrinkled StructureIsrael
-
Venus MedTech (HangZhou) Inc.Not yet recruitingAortic Valve Stenosis
-
Northwell HealthRecruiting
-
Erasme University HospitalBicetre HospitalCompleted